Proactive Investors - Run By Investors For Investors

Arix Biosciences hails phase I success of investee company Pharmaxis

Arix is a cornerstone investor in the ASX life sciences group
Arix Biosciences hails phase I success of investee company Pharmaxis
The two-part phase I clinical study revealed Pharmaxis’ drug was safe and there were no adverse reactions

Arix Biosciences PLC (LON:ARIX) has hailed the early-stage clinical trial success of an Australia-based pharma company in which it has a significant stake.

Pharmaxis (ASX:PXS) is developing what’s called a LOXL2 inhibitor to treat fibrotic diseases such as non-alcoholic steatohepatitis (NASH) and idiopathic pulmonary fibrosis.

WATCH: Aura Biosciences reports positive clinical data on its eye cancer treatment therapy

The two-part phase I clinical study revealed Pharmaxis’ drug was safe and there were no adverse reactions.

The pharmacokinetic profile of the treatment “showed the expected dose related-increases in exposure”, the data revealed. Pharmacokinetics relates to the way the drug is absorbed and distributed.

Repeating the positive results seen in a similar trial for its first inhibitor compound, “excellent drug-like properties [were] demonstrated”, Pharmaxis said.

Arix is a cornerstone investor in the ASX life sciences group and led August’s £13.4mln financing round.

Pharmaxis will host an investor research briefing on Tuesday, 20 November from 10 am to 12.00 noon, (Australian eastern daylight time).

View full ARIX profile View Profile

Arix Bioscience PLC Timeline

Related Articles

harley street
May 10 2019
Work at Advanced Onco’s Harley Street facility is due to complete within the next few months, and the first patient treated by LIGHT is slated for the second half of 2020
Weight loss
January 07 2019
A deal with Indian firm Zeon Lifesciences in January is the ninth deal the firm has secured for the weight loss product
Scientist
December 03 2018
Since September, the group's portfolio has steamed ahead with a number of new and successful clinical trials, as well as a boost from the float of one of its companies on the Nasdaq

© Proactive Investors 2019

Proactive Investors Limited, trading as “Proactiveinvestors United Kingdom”, is Authorised and regulated by the Financial Conduct Authority.
Registered in England with Company Registration number 05639690. Group VAT registration number 872070825 FCA Registration number 559082. You can contact us here.

Market Indices, Commodities and Regulatory News Headlines copyright © Morningstar. Data delayed 15 minutes unless otherwise indicated. Terms of use